The global carbapenem-resistant Enterobacteriaceae (CRE) infection market is experiencing robust growth due to the rising prevalence of multidrug-resistant Gram-negative infections and heightened ...
Recently, a study published in Research (November 24) successfully developed an innovative nanotherapy to combat carbapenem-resistant central nervous system (CNS) infections. The research, titled “BBB ...
Research BackgroundCNS infections caused by carbapenem-resistant Enterobacteriaceae (CRE) pose a critical global healthcare challenge. These ...
Carbapenemase-producing carbapenem-resistant Enterobacterales (CP-CRE) are bacteria capable of neutralizing powerful antibiotics. CP-CRE bacteria are very difficult to treat and potentially deadly, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results